Skip to main content
Virulence logoLink to Virulence
. 2012 Nov 15;3(7):610–620. doi: 10.4161/viru.21823

Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C

Phyllis T Losikoff 1, Alyssa A Self 1, Stephen H Gregory 1,*
PMCID: PMC3545943  PMID: 23076334

Abstract

Hepatitis C virus (HCV) is a small, enveloped RNA virus and a major cause of chronic liver disease. Resolution of primary HCV infections depends upon the vigorous responses of CD4+ and CD8+ T cells to multiple viral epitopes. Although such broad-based responses are readily detected early during the course of infection regardless of clinical outcome, they are not maintained in individuals who develop chronic disease. Ostensibly, a variety of factors contribute to the diminished T cell responses observed in chronic, HCV-infected patients including impaired dendritic cell function and the induction of CD4+FoxP3+ regulatory T cells. Overwhelming evidence suggests that the complex interaction of dendritic cells and regulatory T cells plays a critical role in the pathogenesis of chronic hepatitis C.

Keywords: hepatitis C, chronic liver disease, dendritic cells, FoxP3+ regulatory T cells, tolerance

Introduction

Hepatitis C is an emerging infectious disease caused by hepatitis C virus (HCV). HCV is a small enveloped virus whose RNA genome consists of a large open reading frame that encodes an ~3,000 amino acid poly-protein precursor, which is cleaved by cellular and viral proteases to yield the core, envelope (E1 and E2) and nonstructural (NS) proteins (NS1–NS5) (Fig. 1).1 HCV is a major cause of chronic liver disease and a principal reason for liver transplant; approximately 170 million people worldwide are chronically infected.2,3 HCV is primarily contracted through the transmission of infected blood or body fluids. The risk of transmission via blood and blood products in the US is negligible due to the advent of reliable and mandatory blood screening. Isolated (nosocomial/iatrogenic) outbreaks of hepatitis C continue to occur in US medical facilities, however, emphasizing the vigilance required to enforce universal precautions and proper sterilization of medical devices.4 The infrastructure and technology required to ensure a safe blood supply are elusive for most developing countries where prevalence of HCV infection can be as high as 20% of the population.5 Unfortunately, while only 20% of patients resolve infection spontaneously, the vast majority develops chronic disease.3 Standard hepatitis C treatment consists of the combined administration of PEGylated interferon (IFN) and ribavirin. The response to conventional therapy varies widely, however, and is often accompanied by significant side effects. Only an estimated 45–50% of all patients infected with HCV genotype 1 experience a sustained virologic response upon treatment withdrawal.6 Treatments that include new protease inhibitors, e.g., telaprevir and boceprevir, in conjunction with PEGylated IFN and ribavirin increase the sustained virologic response up to 80% in patients infected with HCV genotype 1.7

graphic file with name viru-3-610-g1.jpg

Figure 1. Hepatitis C virus: structure and genomic organization. The viral genome is enclosed within the core protein and surrounded by an envelope composed of lipid and glycoproteins (A). HCV is a small, enveloped virus with a single-stranded, positive-sense RNA genome that is ~9,600 nucleotide bases long and consists of a single open reading frame. The 5′, ~340 nucleotide long, non-translated region (NTR) functions as an internal ribosome entry site that binds ribosomes in close proximity to the translation start codon. The HCV genome encodes a ~3,000 amino acid poly-protein precursor that is cleaved co- and post- translationally by cellular and viral proteases into ten protein products: C, core; E1 and E2, envelope; NS, nonstructural proteins (NS1–NS5). The function of each cleavage product is shown (B).

HCV-related premature death and morbidity in US patients under 65 y of age are expected to increase 2- to 3-fold between the years 2010 and 2019 at a societal cost exceeding $55 billion.8 Spontaneous clearance is affected by a number of factors that include: age, ethnicity, sex, hepatitis B virus or human immunodeficiency virus co-infection and host genetics (e.g., HLA haplotype and IL28B gene variants).9-13 The majority of new cases in the US occur among young, intravenous drug users.

Resolution of primary HCV infections is associated with the vigorous responses of HLA class I-restricted (CD8+) and class II-restricted (CD4+) T cells to multiple epitopes derived from both structural and non-structural proteins.14 Although such broad-based responses are readily detected early during the course of infection regardless of clinical outcome, they are not maintained in patients who develop chronic disease.15 Thus, while individuals who spontaneously clear infection continue to exhibit a proliferative response to a wide range of class I- and class II-restricted epitopes, chronically infected patients respond to a limited number only.16 A variety of factors purportedly contribute to the diminished T cell responses observed in chronically infected patients including: viral mutation and escape linked to both CD4 and CD8 T cell failure, CD4 T cell anergy, CD8 T cell exhaustion, induction of FoxP3+ regulatory T(reg) cells and/or impaired dendritic cell function.17-26

Dendritic Cells (DCs)

DCs are professional antigen presenting cells characterized by their potent capacity to elicit primary T cell responses.27 Two major subsets of DCs are readily purified from human peripheral blood: plasmacytoid (p)DCs and conventional or myeloid (m)DCs.28-30 Each subset represents 0.3–0.5% of the normal human peripheral blood mononuclear cell (PBMC) population.28,31 mDCs and pDCs originate from myeloid and lymphoid precursors, respectively, residing in the bone marrow.32 pDCs have a round morphology similar to secretory lymphocytes and closely resemble plasma cells.33-35 mDCs, on the other hand, exhibit the typical dendritic cell morphology with prominent cytoplasmic protrusions and veils. Human pDCs and mDCs are further distinguished by the cell surface expression of CD45R/B220+CD123brightCD303+ and CD11c+CD1a+CD1c+, respectively.28-30 mDCs are short lived relative to pDCs, which have a slow turnover rate and a relatively long half-life.35

pDCs and mDCs differ markedly in their ability to capture, process and present antigens, express co-stimulatory molecules and produce cytokines.34 Freshly isolated pDCs express only moderate, heterogeneous levels of HLA-DR, ingest antigens poorly and exhibit diminished allogeneic T cell stimulatory activity in mixed lymphocyte reactions.28 By comparison, mDCs are 10–50 times more efficient in their ability to capture, process and present HLA class I- and class II-restricted antigenic determinants (epitopes) to CD8+ and CD4+ T cells.36

pDCs and mDCs also differ substantially in terms of Toll-like receptor (TLR) expression.33,34,37,38 pDCs strongly express TLR-7 and TLR-9 in the endosomal compartment and respond to single stranded RNA and unmethylated CpG-containing DNA ligands, respectively. Consequently, pDCs are potent mediators of antiviral immunity and unique in their capacity to secrete large quantities of type 1 IFN following virus infection.33-35,39-42 Upon TLR ligation, pDCs upregulate HLA-DR and the cell surface expression of co-stimulatory molecules (e.g., CD80 and CD86), secrete massive amounts of IFN-α/β, acquire T cell stimulatory activity, and induce Th1 cell polarization and the production of IFN-γ.35,39-41 mDCs, on the other hand, recognize viral ligands (e.g., HCV core and NS3) via TLR-2, exhibit elevated HLA-DR levels, specialize in IL-12 production, polarize CD4+ T cells toward Th1 and demonstrate potent allogeneic T cell reactivity.28,37,43-45 In addition, recognition of double-stranded RNA viruses via TLR-3 stimulates the release of large quantities of IL-1, IL-6 and IL-12, and small amounts of type 1 IFN.46

Contribution of DCs to the Pathogenesis of Hepatitis C

Despite extensive investigation, there is no general consensus regarding the effects of HCV on DC function.47 The failure of most patients to manifest clinical symptoms during the acute phase of infection suggests, however, that DC functions are normal at the onset. Moreover, it is generally agreed that the numbers comprising both the pDC and mDC subsets circulating in the peripheral blood are reduced substantially in chronic HCV-infected patients.39-41,47-50 Indeed, the numbers of circulating DCs correlate inversely with serum alanine aminotransferase levels and the severity of liver disease in chronically infected patients.51 It is interesting to note, however, that while the numbers of mDCs and pDCs in the peripheral blood decrease, there is a significant increases in both populations found in the livers of chronic, HCV infected patients.50,52,53 Furthermore, the ratio of mDCs/pDCs is higher in the liver than the peripheral blood of these chronically infected patients suggesting preferential migration of mDCs to areas of liver inflammation.51,52 This has led investigators to speculate that active trafficking and intrahepatic compartmentalization of DCs constitutes the principal mechanism responsible for decreased circulating DCs in chronically infected patients.42,50-52 While the mechanism(s) remains to be clarified, immature DCs in the bloodstream express inflammatory chemokine receptors, e.g., CCR5, and migrate to the liver in response to HCV infection and the elevated production of chemokines, e.g., RANTES, MIP-1α and MIP-1β.53,54 Normally, upon maturation in healthy tissues, DCs downregulate CCR5 and upregulate CCR7 expression enabling the cells to respond to the cognate CCR7 chemokine (CCL21) and traffic to the T cells areas of lymphoid tissues.54,55 In sharp contrast to healthy individuals, however, recent studies demonstrated the expression of CCR5, but not CCR7, by pDCs and mDCs circulating in the blood of HCV-infected patients.42,52,55 Moreover, HCV E2 protein rendered CCR7-expressing DCs unresponsive to CCL21.52 Thus, the attenuated anti-viral response characteristic of chronic, HCV-infected patients appears due in part to the inability of DCs trapped in the liver to home the lymph nodes.50,52

Regardless of their distribution (i.e., liver vs. peripheral blood), contradictory data indicate that functions of pDCs and mDCs are either intact56-63 or impaired36,39,42,44,48,64-74 in patients with chronic hepatitis C. Functional impairments include: decreased IFN-α and IL-12 secretion, increased IL-10 production, lowered expression of HLA-DR and costimulatory molecules such as CD86, decreased allostimulatory activity and increased ability to prime Treg cells.36,39,42,44,48-50,64,65,67-69,75-79 Additional studies reported that DCs obtained from chronically-infected patients were phenotypically immature and failed to upregulate maturation (costimulatory) markers in response to stimuli such as TNF-α.66,73 Circulating pDCs in chronic HCV-infected patients exhibit: diminished HLA-DR expression, a markedly reduced capacity to secrete IFN-α and, consequently, decreased anti-viral potency.36,39,44,67,68,80 mDCs in chronic HCV infections secrete significantly lower levels of IL-12 and increased concentrations of IL-10, which tends to skew the immune response toward tolerance and a reduced ability to induce T-cell proliferation and Th1 polarization.36,47,49,67,69,72,75-77,81 The stimulatory potential of mDCs and the alloreactive response of CD4+ T cells are also diminished in chronic HCV infections.44 Although the literature addressing mDCs function during acute HCV infection is limited, patients who exhibit decreased mDC allostimulatory activity seem to exhibit an increased chance of developing viral persistence.71 In sharp contrast to chronically infected patients in whom DCs are impaired, DCs derived from the peripheral blood of healthy individuals and patients who spontaneously cleared HCV infection were phenotypically comparable and functionally normal.42,66

The mechanisms underlying DC dysfunction during HCV infection are not fully understood. The core, NS3, NS4 and NS5 proteins impair DC function by diminishing the HLA and co-stimulatory molecule expression, reducing cytokine production, inhibiting TLR signaling, and decreasing allostimulatory activity.82 The HCV core protein induces IL-10/TNF-α secretion by monocytes, which triggers pDC apoptosis and, indirectly, reduces IFN-α secretion.49,83 Similarly, IL-10 produced by monocytes in response to core, NS3 and/or NS4 proteins impairs DC maturation, reduces allostimulatory activity, suppresses IL-12 production and, consequently, interferes with Th1 polarization.72,77,84-86

Conflicting evidence, however, shows that DCs in chronic HCV infected patients are neither functionally nor phenotypically impaired and exhibit normal activity.56,57,87 DCs in chronically infected patients express typical maturation markers and CD83, CD86, CD54 and HLA-DR levels similar to those expressed by healthy patients.56,88 Additionally, DCs derived from healthy subjects and patients with chronic HCV infections demonstrate comparable abilities to prime allogeneic T cells.56,60,88 Healthy and infected patients secrete similar quantities of IL-12 and IFN-α.57-60 DCs derived from chronically-infected patients exhibited normal antigen uptake, peptide-MHC complex formation, and antigen trafficking suggesting that the capacity to present antigen is preserved during HCV infection.63

A variety of factors contribute to these discrepant results including: (1) the limited number of patients enrolled in studies; (2) patient related factors such as age, gender, co-infection and alcohol use; (3) duration of infection, liver inflammation and disease progression; (4) tissue source of DCs analyzed (i.e., peripheral blood vs. liver) and (5) whether the data originate from freshly isolated DCs or monocyte-derived DCs obtained from chronic HCV-infected patients.47 Indeed, given the paucity of DCs in the bloodstream and the challenge of tissue acquisition, most human studies are conducted with DCs generated in vitro from CD14+ monocyte precursors present in the peripheral blood. The differentiation of monocyte-derived DCs in vitro resembles the development of mDCs in vivo; notably, pDCs are not readily expand or derive in vitro.71,89

Regulatory T Cells

CD4+ regulatory T(reg) cells, characterized by the transcription factor forkhead box P3 (FoxP3) and the constitutive, cell-surface expression of the interleukin (IL)-2 receptor α chain (CD25), represent one of the major mechanisms underlying immunological self-tolerance and homeostasis.90 Mutations in FoxP3 and Treg cell dysregulation cause severe autoimmune disease and immunopathology leading to death in both mice and humans.91,92 Treg cells also constitute an important factor in moderating effector immune responses to pathogens that can potentially cause serious organ and tissue damage to the host if left unabated.93 Though critical for maintaining immune homeostasis, Treg cells can also suppress effective immune responses to autologous tumors, e.g., metastatic melanoma and hematological malignancies, and contribute to the persistence of infections by a wide variety of human pathogens.93-95

Two types of Treg cells are commonly described in the literature and classically distinguished by site of origin: natural (n)Treg cells generated by high-avidity selection in the thymus; and adaptive or inducible (i)Treg cells derived from antigen-stimulated conventional (CD4+CD25-FoxP3-) T cells in the periphery (Fig. 2).96,97 nTreg cells can induce “infectious tolerance” by converting conventional T cells into iTreg cells directly by cytokine (IL-10, TGF-β or IL-35)-dependent mechanisms or -independent mechanisms mediated by contact with DCs.98,99 It has been suggested that nTreg and iTreg cells express complementary, immune functions, that nTreg cells and iTreg cells are dedicated to preventing autoimmunity and to maintaining a non-inflammatory environment, respectively.96 Notably, there are no definitive markers that identify Treg cells, or distinguish nTreg and iTreg subsets. While FoxP3 is a transcription factor common to both subsets, it is also expressed transiently by activated, conventional human T cells that do not exhibit immunosuppressive activity.97 Moreover, while CD25+ T cells isolated from naïve mice are almost exclusively nTreg cells; CD25 expression in humans is much more heterogeneous.97

graphic file with name viru-3-610-g2.jpg

Figure 2. FoxP3+ Treg cell production in the thymus and periphery. Natural (n)Treg cells are generated by high-avidity selection in the thymus. Inducible (i)Treg cells derive from antigen-stimulated naïve T cells in the periphery. nTreg cells can promote iTreg cell development by cytokine-dependent mechanisms (infectious tolerance).

Once activated, Treg cells are able to suppress the activity of a wide range of immune cell types including both CD4+ and CD8+ T cell subsets, B cells, NK cells, NKT cells, macrophages and DCs (a phenomenon called bystander suppression).100-105 Suppression can be mediated by multiple mechanisms although it is generally agreed that the effects of nTreg cells are primarily mediated by direct, cell-to-cell contact.105

Inhibitory cytokines constitute a principal contact-independent mechanism by which Treg cells suppress Teff cell activity (Fig. 3). Soluble and membrane-bound transforming grow factor (TGF)-β, for example, play a critical role both in inducing and maintaining nTreg and iTreg cells, and in blocking the activation of conventional Teff cell.103,106-108 Similarly, Treg cell-dependent production of interleukin 10 (IL-10), plays an important role in suppressing the responses of CD4+ Teff cells to a variety of pathogens both used in animal models and implicated in human disease.93

graphic file with name viru-3-610-g3.jpg

Figure 3. Mechanisms mediating Treg cell suppression. FoxP3+ Treg cells suppress Teff cell activity (A). Treg cells inhibit Teff cell activity by multiple contact-dependent and -independent mechanisms described in the text. FoxP3+ Treg cells impair DC function (B). Similarly, Treg cells impair DC maturation and function by mechanisms described in the text.

Contact-independent mechanisms of Treg cell-mediated suppression also involve the constitutive, high-level expression of the IL-2 receptor (CD25). Treg cells are capable of relatively little IL-2 production and, consequently, require IL-2 derived from an exogenous source.109 As such, the rapid consumption of IL-2 by Treg cells deprives Teff cell populations of IL-2 necessary for activation and proliferation.109 Cell surface nucleotidase activity (i.e., CD39 and CD73) constitutes an additional mechanism by which Treg cells disrupt the metabolic activity of Teff cells.110 These ectonucleotidases rapidly degrade extracellular ATP released by activated or damage cells and abrogate the proinflammatory response that would otherwise occur.110 In addition, adenosine generated as a product of ATP degradation binds A2A receptors expressed by T cells and prevents effector cell activation.110-112

Treg cells also exhibit the ability to suppress Teff cell function by a number of contact-dependent mechanisms. Both mouse and human Treg cells, for example, exhibit cytotoxic activity and the ability to induce apoptosis by Teff cells dependent upon granzyme A or B and perforin.108,113 Galectin-1, a member of a highly conserved family of β-galactosidase-binding proteins, has also been implicated in the immunosuppressive activity exhibited by Treg cells.114 Galectin-1, expressed on the cell surface, inhibits cell proliferation and promotes apoptosis by activated Teff cells

In addition to regulating Teff cell functions directly, Treg cells can suppress conventional T cell activity indirectly by inhibiting DC maturation and immunostimulatory activity.108 In a process called trans-endocytosis, for example, cytotoxic T lymphocyte-4 (CTLA-4) molecules on the surface of Treg cells capture, internalize and degrade CD80 and CD86 expressed by DCs rendering the latter tolerogenic and limited in their capacity to sensitize naïve Teff cells.115 Similarly, lymphocyte activation gene-3 (LAG-3 of CD223), a CD4 homolog that binds MHC class II molecules, suppresses DC maturation and co-stimulatory molecule expression.116,117 Neuropilin (Nrp-1), a molecule also expressed by Treg cells, promotes long-term Treg cell interaction with immature DCs and, thus, inhibits immune recognition by naïve CD4+ helper T cells.118 Notably, the suppressor functions of Treg cells undoubtedly rely upon a combination of all the factors described. Moreover, it is likely that one or more of these factors affect both Teff cells and DCs, as well as other immune cell types.

Contribution of Treg Cells to the Pathogenesis of Hepatitis C

Treg cells play a prominent role in the pathogenesis of chronic HCV infection. This role was first suggested based upon the increased frequency of Treg cells found in the liver and circulating in the peripheral blood of chronically-infected patients compared with uninfected individuals or patients who spontaneously cleared the virus.23,24,93,119-123 Moreover, CD4+CD25+ T cells isolated from the blood of HCV-infected patients suppressed virus-specific CD8 T cell responses, while depletion of the CD25+ T cell population enhanced the proliferation of cells that remained.23,123 Until recently, however, it remained unclear whether this increase in Treg cells represented an HCV antigen-specific response or occurred as a nonspecific consequence of chronic inflammation and liver disease. Furthermore, descriptions in literature of the phenotype and function of the Treg cell populations are not consistent.

HCV-encoded Treg cell epitopes have now been identified in both structural (i.e., core) and non-structural (NS3, NS4 and NS5b) proteins.119,120,124-127 Utilizing dye-conjugated, HCV peptide-loaded MHC class II tetramers to stain the cell, Ebinuma and coworkers were the first to report HCV antigen-specific recognition by FoxP3+ Treg cells contained among the PBMCs derived from chronically infected patients.124 A number of studies have demonstrated an increase in the HCV-antigen specific FoxP3+/CD25high cell population (phenotypically similar to nTreg cells expressing an anergic cytokine profile) in response to stimulation with HCV T regulatory epitopes.119,121,124 In one study, global gene expression analysis comparing FACS-sorted CD4+/CD25high T cells (nTreg phenotype) from HCV-infected and uninfected individuals found only minimal differences between the two populations.124 In contrast, other investigators observed an increase in HCV antigen-specific Treg cells phenotypically consistent with iTreg cells, which induced suppression via induction of IL-10 or TGF-β.120,126 Regardless, the consensus seems to be that the expanded Treg cell population in chronically infected HCV patients is heterogeneous, composed of both nTreg and iTreg cell subsets. Conceivably, the initial HCV epitope-specific response of nTreg cells to infection induces the expansion of, and subsequent suppression by, iTreg cells (i.e., infectious tolerance).98

The response of nTreg cells, which normally function to suppress autoimmunity, suggests that HCV encodes peptide (epitope) sequences homologous to self-antigen.119,128 Indeed, a BLAST search of the viral genome identified a number of Treg cell-epitopes published in the literature that exhibited extensive human homology (Ardito and Losikoff, unpublished observation). While these epitopes elicited a response by Treg cells circulating in the bloodstream of chronic, HCV-infected patients, they failed to elicit a similar response by cells obtained from healthy controls.119 This seems to imply that these HCV-specific nTreg cell populations expand in vivo during chronic disease.122,129 It is relevant to note, therefore, that many published epitopes recognized by HCV-specific Treg cells are located adjacent to or overlapping with Teff cell epitopes associated with viral clearance.119,124,130

Several cross-sectional studies demonstrated a strong correlation between increased Treg cell numbers and chronic HCV infection.23,123,124 The specific role of Treg cells in viral persistence could not be determined, however, since the patients were previously infected at some undetermined date. In this regard, two longitudinal studies involving patients acutely infected with HCV reported no difference in the frequency or function of circulating Treg cells irrespective of whether the patient ultimately cleared virus or developed chronic disease.121,130 In one study, Treg cells derived from patients in whom viremia persisted exhibited significantly more suppressive activity in vitro than did cells obtained from patients who spontaneously cleared the virus.121 The authors concluded that maintaining an elevated Treg cell population regulated (suppressed) the Teff cell response and promoted the development of chronicity.

Recently, Cusick et al. reported that a variant of an immunodominant HCV epitope emerged during the course of persistent HCV infection.127 This epitope variant induced a population of Foxp3+CD4+ Treg cells that was able to suppress the response of Teff cells to the cognate, but not an unrelated, peptide. Thus, variants of MHC class II-restricted epitopes arise as a consequence of immune pressure to evade host defenses, and these variants induce epitope-specific Treg cells that attenuate conventional CD4+ T cell help required to clear virus infection. In cases of chronic disease, Treg cells suppress virus-specific CD4 T cell activity, impairing maintenance of Teff cell function and promoting viral persistence.

Impaired DCs, Treg Cells and the Pathogenesis of Chronic HCV

It is not entirely clear whether HCV affects the response of Treg cells to infection directly or indirectly, dependent upon the intermediary role of some other cell type. There is accumulating evidence to suggest, however, that DCs play a key role in the expansion of Treg cells during chronic HCV infection. Indeed, HCV proteins (core, NS3, NS4 and NS5) exert a marked, inhibitory effect on the capacity of DCs derived from healthy individuals to express HLA and cell surface co-stimulatory molecules, synthesize proinflammatory cytokines such as IL-12 and induce allogeneic T cell proliferation.82 These same viral proteins failed to affect T cell proliferation directly, supporting the contention that the effect of HCV on Teff cell function depends upon the intermediary role of DCs.82 Recent studies suggest, however, that both DCs and conventional Teff cells are susceptible to HCV infection.131-133 In the former case, the binding and subsequent internalization of viral particles are mediated by the interaction of envelope glycoproteins E1 and E2 with dendritic cell-specific C-type lectin (DC-SIGN), a cell surface receptor expressed by DCs.133 Consequently, the authors speculated that even in the absence of a productive infection, HCV E1 and E2 bound to DC-SIGN might transmit a signal that promoted tolerance and Treg cell formation. In the case of CD4+ T cells, Dominguez-Villar and coworkers reported that the Jurkat T cell line transfected with an HCV core-expressing vector upregulated FoxP3 and CTLA-4, and acquired the ability to suppress the non-specific proliferative response of both CD4+ and CD8+ T cells.134 This latter finding implies the potential capacity of HCV infection alone to induce Treg cells formation.

While the virus may infect T cells and DCs directly, impaired DC function appears to play a key role in the induction and maintenance of HCV-specific Treg cell responses. In this regard, overwhelming evidence supports the role of DCs in establishing and maintaining immunological tolerance to foreign, as well as self, antigens.135,136 In particular, the liver provides a prototypical tolerogenic environment in which interactions that include DCs and Treg cells foster development of chronic infectious diseases, e.g., viral hepatitis.137 While the underlying mechanisms remain to be delineated fully, it is generally agreed that immature DCs promote Treg cell function.135-139 It is pertinent to note, therefore, that DCs purified from human liver tissue primarily express an immature, myeloid phenotype characterized by the low-level or negligible expression of cell-surface co-stimulatory molecules: CD40, CD80, CD83 and CD86.137 Moreover, compared with DCs purified from peripheral blood, liver DCs produce significantly higher levels of IL-10 and lower proinflammatory cytokine (i.e., IL-1β, IL-6 and TNF-α) levels following TLR4 ligation. Finally, compared with DCs in the blood, liver DCs stimulated the IL-10-dependent production of more CD4+CD25+FoxP3+ Treg cells in co-cultures that contained naïve, allogeneic CD4+ T cells.138 Similar results were found when allogeneic T cells were co-cultured with mDCs obtained from healthy control and chronic, HCV-infected patients.79 Relative to the controls, mDCs derived from infected patients stimulated a marked expansion of Treg cells.

Summary

DCs circulating in the peripheral blood of chronic, HCV-infected patients are functionally impaired. Both pDCs and mDCs are reduced in number and exhibit decreases in: cytokine production, cell-surface co-stimulatory molecule expression and/or allostimulatory activity, resulting in an inability to prime naïve Teff cells and, consequently, a reduction in anti-viral activity (Fig. 4). On the other hand, the number and function of Treg cells in the blood of these same patients are increased correlating with the development of persistent viral infection. Treg cells can suppress the activity of other immune cell types including Teff cells directly by contact-dependent and -independent mechanisms, or indirectly by inhibiting DC maturation and immunostimulatory capacity. As such, recent studies indicate that immature DCs are a critical factor in the pathogenesis of chronic hepatitis C by failing to induce adequately naïve Teff cell function and, conversely, promoting the development and activity of Treg cells.

graphic file with name viru-3-610-g4.jpg

Figure 4. Immune suppression mechanisms in HCV infection. Both the number and functions of circulating mDCs and pDCs are diminished in cases of chronic hepatitis C. Immature DCs promote the expansion and function of FoxP3+ Treg cells. Treg cells, in turn, suppress CD4+ and CD8+ T cell, NK cell, NKT cell, B cell, macrophage and DC activities. Red and blue arrows indicate activation and suppression, respectively.

Acknowledgments

Support was provided by National Institutes of Health Research Grant U19 AI082642.

Glossary

Abbreviations:

CCL

chemokine ligand

CCR

chemokine receptor

FoxP3

transcription factor forkhead box P3

HCV

hepatitis C virus

IFN

interferon

IL

interleukin

iTreg cell

inducible regulatory T cell

mDCs

myeloid dendritic cells

nTreg cell

natural regulatory T cell

NS

non-structural

pDCs

plasmacytoid dendritic cells

Teff cells

effector T cells

TLR

toll-like receptor

TGF-β

transforming growth factor-beta

Footnotes

References

  • 1.Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993;67:1385–95. doi: 10.1128/jvi.67.3.1385-1395.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899–905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  • 3.El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(Suppl 1):S74–83. doi: 10.1002/hep.1840360710. [DOI] [PubMed] [Google Scholar]
  • 4.Healthcare-associated hepatitis B and C outbreaks reported to the Centers for Disease Control and Prevention (CDC) in 2008-2011. CDC Website 2012.
  • 5.Brown RS, Jr., Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 2003;9:S10–3. doi: 10.1053/jlts.2003.50244. [DOI] [PubMed] [Google Scholar]
  • 6.Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. International Hepatitis Interventional Therapy Group Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493–9. doi: 10.1056/NEJM199811193392102. [DOI] [PubMed] [Google Scholar]
  • 7.Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology. 2012;142:1340–50, e1. doi: 10.1053/j.gastro.2012.02.015. [DOI] [PubMed] [Google Scholar]
  • 8.Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562–9. doi: 10.2105/AJPH.90.10.1562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis. 2004;190:1270–4. doi: 10.1086/423943. [DOI] [PubMed] [Google Scholar]
  • 10.Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics. 2009;10:1819–37. doi: 10.2217/pgs.09.121. [DOI] [PubMed] [Google Scholar]
  • 11.Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012;19:173–81. doi: 10.1111/j.1365-2893.2011.01497.x. [DOI] [PubMed] [Google Scholar]
  • 12.Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology. 1998;27:240–4. doi: 10.1002/hep.510270136. [DOI] [PubMed] [Google Scholar]
  • 13.Neumann-Haefelin C. [Protective role of HLA-B27 in HIV and hepatitis C virus infection] Dtsch Med Wochenschr. 2011;136:320–4. doi: 10.1055/s-0031-1272531. [DOI] [PubMed] [Google Scholar]
  • 14.Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000;191:1499–512. doi: 10.1084/jem.191.9.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med. 2012;209:61–75. doi: 10.1084/jem.20100388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002;76:12584–95. doi: 10.1128/JVI.76.24.12584-12595.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol. 2007;13:2416–26. doi: 10.3748/wjg.v13.i17.2416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology. 2010;51:378–87. doi: 10.1002/hep.23319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med. 2005;201:1725–31. doi: 10.1084/jem.20042284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W, et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology. 2003;37:1189–98. doi: 10.1053/jhep.2003.50194. [DOI] [PubMed] [Google Scholar]
  • 21.Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol. 2001;75:5550–8. doi: 10.1128/JVI.75.12.5550-5558.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002;169:3447–58. doi: 10.4049/jimmunol.169.6.3447. [DOI] [PubMed] [Google Scholar]
  • 23.Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 2004;40:1062–71. doi: 10.1002/hep.20454. [DOI] [PubMed] [Google Scholar]
  • 24.Ward SM, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol. 2007;47:316–24. doi: 10.1016/j.jhep.2007.03.023. [DOI] [PubMed] [Google Scholar]
  • 25.Claassen MA, de Knegt RJ, Tilanus HW, Janssen HL, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol. 2010;52:315–21. doi: 10.1016/j.jhep.2009.12.013. [DOI] [PubMed] [Google Scholar]
  • 26.Gowans EJ, Jones KL, Bharadwaj M, Jackson DC. Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol. 2004;30:283–90. doi: 10.1016/j.jcv.2004.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52. doi: 10.1038/32588. [DOI] [PubMed] [Google Scholar]
  • 28.O’Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology. 1994;82:487–93. [PMC free article] [PubMed] [Google Scholar]
  • 29.Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165:6037–46. doi: 10.4049/jimmunol.165.11.6037. [DOI] [PubMed] [Google Scholar]
  • 30.Kadowaki N. The divergence and interplay between pDC and mDC in humans. Front Biosci. 2009;14:808–17. doi: 10.2741/3279. [DOI] [PubMed] [Google Scholar]
  • 31.Tavakoli S, Mederacke I, Herzog-Hauff S, Glebe D, Grün S, Strand D, et al. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol. 2008;151:61–70. doi: 10.1111/j.1365-2249.2007.03547.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2:151–61. doi: 10.1038/nri746. [DOI] [PubMed] [Google Scholar]
  • 33.Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275–306. doi: 10.1146/annurev.immunol.23.021704.115633. [DOI] [PubMed] [Google Scholar]
  • 34.Barchet W, Cella M, Colonna M. Plasmacytoid dendritic cells--virus experts of innate immunity. Semin Immunol. 2005;17:253–61. doi: 10.1016/j.smim.2005.05.008. [DOI] [PubMed] [Google Scholar]
  • 35.Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol. 2011;29:163–83. doi: 10.1146/annurev-immunol-031210-101345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Averill L, Lee WM, Karandikar NJ. Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol. 2007;123:40–9. doi: 10.1016/j.clim.2006.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863–9. doi: 10.1084/jem.194.6.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, Aït-Yahia S, et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol. 1998;160:1666–76. [PubMed] [Google Scholar]
  • 39.Ulsenheimer A, Gerlach JT, Jung MC, Gruener N, Wächtler M, Backmund M, et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology. 2005;41:643–51. doi: 10.1002/hep.20592. [DOI] [PubMed] [Google Scholar]
  • 40.Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5:1219–26. doi: 10.1038/ni1141. [DOI] [PubMed] [Google Scholar]
  • 41.Takahashi K, Asabe S, Wieland S, Garaigorta U, Gastaminza P, Isogawa M, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A. 2010;107:7431–6. doi: 10.1073/pnas.1002301107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Mengshol JA, Golden-Mason L, Castelblanco N, Im KA, Dillon SM, Wilson CC, et al. Virahep-C Study Group Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut. 2009;58:964–73. doi: 10.1136/gut.2008.168948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Hellman P, Eriksson H. Early activation markers of human peripheral dendritic cells. Hum Immunol. 2007;68:324–33. doi: 10.1016/j.humimm.2007.01.018. [DOI] [PubMed] [Google Scholar]
  • 44.Szabo G, Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology. 2005;210:237–47. doi: 10.1016/j.imbio.2005.05.018. [DOI] [PubMed] [Google Scholar]
  • 45.Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology. 2004;127:1513–24. doi: 10.1053/j.gastro.2004.08.067. [DOI] [PubMed] [Google Scholar]
  • 46.Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J. Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol. 2007;247:72–84. doi: 10.1016/j.cellimm.2007.07.008. [DOI] [PubMed] [Google Scholar]
  • 47.Ryan EJ, O’Farrelly C. The affect of chronic hepatitis C infection on dendritic cell function: a summary of the experimental evidence. J Viral Hepat. 2011;18:601–7. doi: 10.1111/j.1365-2893.2011.01453.x. [DOI] [PubMed] [Google Scholar]
  • 48.Wertheimer AM, Bakke A, Rosen HR. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology. 2004;40:335–45. doi: 10.1002/hep.20306. [DOI] [PubMed] [Google Scholar]
  • 49.Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745–54. doi: 10.1172/JCI39133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Cicinnati VR, Kang J, Sotiropoulos GC, Hilgard P, Frilling A, Broelsch CE, et al. Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. J Gen Virol. 2008;89:1243–53. doi: 10.1099/vir.0.83517-0. [DOI] [PubMed] [Google Scholar]
  • 51.Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J Hepatol. 2002;36:734–41. doi: 10.1016/S0168-8278(02)00062-4. [DOI] [PubMed] [Google Scholar]
  • 52.Nattermann J, Zimmermann H, Iwan A, von Lilienfeld-Toal M, Leifeld L, Nischalke HD, et al. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology. 2006;44:945–54. doi: 10.1002/hep.21350. [DOI] [PubMed] [Google Scholar]
  • 53.Wald O, Weiss ID, Galun E, Peled A. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Cytokine. 2007;39:50–62. doi: 10.1016/j.cyto.2007.05.013. [DOI] [PubMed] [Google Scholar]
  • 54.Sozzani S, Allavena P, Vecchi A, Mantovani A. Chemokines and dendritic cell traffic. J Clin Immunol. 2000;20:151–60. doi: 10.1023/A:1006659211340. [DOI] [PubMed] [Google Scholar]
  • 55.Sallusto F, Lanzavecchia A. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med. 1999;189:611–4. doi: 10.1084/jem.189.4.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood. 2004;103:1026–9. doi: 10.1182/blood-2003-04-1339. [DOI] [PubMed] [Google Scholar]
  • 57.Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis. 2005;192:497–503. doi: 10.1086/431523. [DOI] [PubMed] [Google Scholar]
  • 58.Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol. 2005;42:61–7. doi: 10.1016/j.jhep.2004.09.014. [DOI] [PubMed] [Google Scholar]
  • 59.Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med. 2007;204:2423–37. doi: 10.1084/jem.20070814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Barnes E, Salio M, Cerundolo V, Francesco L, Pardoll D, Klenerman P, et al. Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat. 2008;15:219–28. doi: 10.1111/j.1365-2893.2007.00934.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Liang CC, Liu CH, Lin YL, Liu CJ, Chiang BL, Kao JH. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. J Med Virol. 2011;83:1212–20. doi: 10.1002/jmv.22096. [DOI] [PubMed] [Google Scholar]
  • 62.Albert ML, Decalf J, Pol S. Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C. J Hepatol. 2008;49:1069–78. doi: 10.1016/j.jhep.2008.09.002. [DOI] [PubMed] [Google Scholar]
  • 63.Canaday DH, Burant CJ, Jones L, Aung H, Woc-Colburn L, Anthony DD. Preserved MHC-II antigen processing and presentation function in chronic HCV infection. Cell Immunol. 2011;266:187–91. doi: 10.1016/j.cellimm.2010.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol. 1999;162:5584–91. [PubMed] [Google Scholar]
  • 65.Bain C, Fatmi A, Zoulim F, Zarski JP, Trépo C, Inchauspé G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology. 2001;120:512–24. doi: 10.1053/gast.2001.21212. [DOI] [PubMed] [Google Scholar]
  • 66.Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood. 2001;97:3171–6. doi: 10.1182/blood.V97.10.3171. [DOI] [PubMed] [Google Scholar]
  • 67.Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman MM, et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol. 2004;172:4907–16. doi: 10.4049/jimmunol.172.8.4907. [DOI] [PubMed] [Google Scholar]
  • 68.Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin Exp Immunol. 2004;137:559–65. doi: 10.1111/j.1365-2249.2004.02550.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Della Bella S, Crosignani A, Riva A, Presicce P, Benetti A, Longhi R, et al. Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology. 2007;121:283–92. doi: 10.1111/j.1365-2567.2007.02577.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Yonkers NL, Rodriguez B, Milkovich KA, Asaad R, Lederman MM, Heeger PS, et al. TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol. 2007;178:4436–44. doi: 10.4049/jimmunol.178.7.4436. [DOI] [PubMed] [Google Scholar]
  • 71.Dolganiuc A, Szabo G. Dendritic cells in hepatitis C infection: can they (help) win the battle? J Gastroenterol. 2011;46:432–47. doi: 10.1007/s00535-011-0377-y. [DOI] [PubMed] [Google Scholar]
  • 72.Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L, Jr., et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol. 2003;170:5615–24. doi: 10.4049/jimmunol.170.11.5615. [DOI] [PubMed] [Google Scholar]
  • 73.Gelderblom HC, Nijhuis LE, de Jong EC, te Velde AA, Pajkrt D, Reesink HW, et al. Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile. Liver Int. 2007;27:944–53. doi: 10.1111/j.1478-3231.2007.01507.x. [DOI] [PubMed] [Google Scholar]
  • 74.MacDonald AJ, Semper AE, Libri NA, Rosenberg WM. Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells. Clin Exp Immunol. 2007;148:494–500. doi: 10.1111/j.1365-2249.2007.03367.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, et al. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis. 2004;190:1919–26. doi: 10.1086/425425. [DOI] [PubMed] [Google Scholar]
  • 76.Saito K, Ait-Goughoulte M, Truscott SM, Meyer K, Blazevic A, Abate G, et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol. 2008;82:3320–8. doi: 10.1128/JVI.02547-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Brady MT, MacDonald AJ, Rowan AG, Mills KH. Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol. 2003;33:3448–57. doi: 10.1002/eji.200324251. [DOI] [PubMed] [Google Scholar]
  • 78.Gerlach JT, Ulsenheimer A, Grüner NH, Jung MC, Schraut W, Schirren CA, et al. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J Virol. 2005;79:12425–33. doi: 10.1128/JVI.79.19.12425-12433.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Dolganiuc A, Paek E, Kodys K, Thomas J, Szabo G. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology. 2008;135:2119–27. doi: 10.1053/j.gastro.2008.07.082. [DOI] [PubMed] [Google Scholar]
  • 80.Amjad M, Abdel-Haq N, Faisal M, Kamal M, Moudgal V. Decreased interferon-α production and impaired regulatory function of plasmacytoid dendritic cells induced by the hepatitis C virus NS 5 protein. Microbiol Immunol. 2008;52:499–507. doi: 10.1111/j.1348-0421.2008.00067.x. [DOI] [PubMed] [Google Scholar]
  • 81.Pachiadakis I, Chokshi S, Cooksley H, Farmakiotis D, Sarrazin C, Zeuzem S, et al. Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Clin Immunol. 2009;131:415–25. doi: 10.1016/j.clim.2009.02.001. [DOI] [PubMed] [Google Scholar]
  • 82.Krishnadas DK, Ahn JS, Han J, Kumar R, Agrawal B. Immunomodulation by hepatitis C virus-derived proteins: targeting human dendritic cells by multiple mechanisms. Int Immunol. 2010;22:491–502. doi: 10.1093/intimm/dxq033. [DOI] [PubMed] [Google Scholar]
  • 83.Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, Cormier M, et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-α and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol. 2006;177:6758–68. doi: 10.4049/jimmunol.177.10.6758. [DOI] [PubMed] [Google Scholar]
  • 84.Takaki A, Tatsukawa M, Iwasaki Y, Koike K, Noguchi Y, Shiraha H, et al. Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells. J Viral Hepat. 2010;17:555–62. doi: 10.1111/j.1365-2893.2009.01213.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol. 2003;77:10862–71. doi: 10.1128/JVI.77.20.10862-10871.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol. 2008;128:133–47. doi: 10.1016/j.clim.2008.03.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, et al. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol. 1998;28:3448–55. doi: 10.1002/(SICI)1521-4141(199811)28:11<3448::AID-IMMU3448>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  • 88.Landi A, Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Human dendritic cells expressing hepatitis C virus core protein display transcriptional and functional changes consistent with maturation. J Viral Hepat. 2011;18:700–13. doi: 10.1111/j.1365-2893.2010.01357.x. [DOI] [PubMed] [Google Scholar]
  • 89.Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science. 1998;282:480–3. doi: 10.1126/science.282.5388.480. [DOI] [PubMed] [Google Scholar]
  • 90.Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500. doi: 10.1038/nri2785. [DOI] [PubMed] [Google Scholar]
  • 91.Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–1. doi: 10.1038/83713. [DOI] [PubMed] [Google Scholar]
  • 92.Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4:337–42. doi: 10.1038/ni909. [DOI] [PubMed] [Google Scholar]
  • 93.Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions (*) Annu Rev Immunol. 2009;27:551–89. doi: 10.1146/annurev.immunol.021908.132723. [DOI] [PubMed] [Google Scholar]
  • 94.Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239–44. doi: 10.1038/ni1572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27:635–46. doi: 10.1016/j.immuni.2007.08.014. [DOI] [PubMed] [Google Scholar]
  • 96.Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 2009;30:626–35. doi: 10.1016/j.immuni.2009.05.002. [DOI] [PubMed] [Google Scholar]
  • 97.Miyara M, Sakaguchi S. Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol Cell Biol. 2011;89:346–51. doi: 10.1038/icb.2010.137. [DOI] [PubMed] [Google Scholar]
  • 98.Gravano DM, Vignali DA. The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci. 2012;69:1997–2008. doi: 10.1007/s00018-011-0907-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med. 2002;196:255–60. doi: 10.1084/jem.20020394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107:3925–32. doi: 10.1182/blood-2005-11-4502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 2006;214:229–38. doi: 10.1111/j.1600-065X.2006.00445.x. [DOI] [PubMed] [Google Scholar]
  • 102.La Cava A, Van Kaer L, Fu-Dong-Shi CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol. 2006;27:322–7. doi: 10.1016/j.it.2006.05.003. [DOI] [PubMed] [Google Scholar]
  • 103.Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30:636–45. doi: 10.1016/j.immuni.2009.04.010. [DOI] [PubMed] [Google Scholar]
  • 104.Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253–7. doi: 10.1038/nri1032. [DOI] [PubMed] [Google Scholar]
  • 105.Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13:108–16. doi: 10.1016/j.molmed.2007.01.003. [DOI] [PubMed] [Google Scholar]
  • 106.Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ, et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med. 2008;205:1975–81. doi: 10.1084/jem.20080308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature. 1992;359:693–9. doi: 10.1038/359693a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–32. doi: 10.1038/nri2343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol. 2011;23:424–30. doi: 10.1016/j.smim.2011.10.002. [DOI] [PubMed] [Google Scholar]
  • 110.Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225–32. doi: 10.1182/blood-2006-12-064527. [DOI] [PubMed] [Google Scholar]
  • 111.Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009;23:1685–93. doi: 10.1096/fj.08-126458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257–65. doi: 10.1084/jem.20062512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Ren X, Ye F, Jiang Z, Chu Y, Xiong S, Wang Y. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells. Cell Death Differ. 2007;14:2076–84. doi: 10.1038/sj.cdd.4402220. [DOI] [PubMed] [Google Scholar]
  • 114.Garín MI, Chu CC, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood. 2007;109:2058–65. doi: 10.1182/blood-2006-04-016451. [DOI] [PubMed] [Google Scholar]
  • 115.Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600–3. doi: 10.1126/science.1202947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503–13. doi: 10.1016/j.immuni.2004.08.010. [DOI] [PubMed] [Google Scholar]
  • 117.Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180:5916–26. doi: 10.4049/jimmunol.180.9.5916. [DOI] [PubMed] [Google Scholar]
  • 118.Sarris M, Andersen KG, Randow F, Mayr L, Betz AG. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity. 2008;28:402–13. doi: 10.1016/j.immuni.2008.01.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Li S, Jones KL, Woollard DJ, Dromey J, Paukovics G, Plebanski M, et al. Defining target antigens for CD25+ FOXP3 + IFN-γ- regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol. 2007;85:197–204. doi: 10.1038/sj.icb.7100020. [DOI] [PubMed] [Google Scholar]
  • 120.MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J, et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis. 2002;185:720–7. doi: 10.1086/339340. [DOI] [PubMed] [Google Scholar]
  • 121.Smyk-Pearson S, Golden-Mason L, Klarquist J, Burton JR, Jr., Tester IA, Wang CC, et al. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis. 2008;197:46–57. doi: 10.1086/523651. [DOI] [PubMed] [Google Scholar]
  • 122.Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol. 2005;79:7860–7. doi: 10.1128/JVI.79.12.7860-7867.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 2003;38:1437–48. doi: 10.1016/j.hep.2003.09.026. [DOI] [PubMed] [Google Scholar]
  • 124.Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, et al. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol. 2008;82:5043–53. doi: 10.1128/JVI.01548-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, et al. Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog. 2009;5:e1000707. doi: 10.1371/journal.ppat.1000707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Langhans B, Braunschweiger I, Arndt S, Schulte W, Satoguina J, Layland LE, et al. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci (Lond) 2010;119:97–109. doi: 10.1042/CS20090661. [DOI] [PubMed] [Google Scholar]
  • 127.Cusick MF, Schiller JJ, Gill JC, Eckels DD. Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses. Clin Dev Immunol. 2011;2011:806061. doi: 10.1155/2011/806061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Mishiro S, Takeda K, Hoshi Y, Yoshikawa A, Gotanda T, Itoh Y. An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen. Autoimmunity. 1991;10:269–73. doi: 10.3109/08916939109001900. [DOI] [PubMed] [Google Scholar]
  • 129.Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol. 2005;79:7852–9. doi: 10.1128/JVI.79.12.7852-7859.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Heeg MH, Ulsenheimer A, Grüner NH, Zachoval R, Jung MC, Gerlach JT, et al. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology. 2009;137:1280–8, e1-6. doi: 10.1053/j.gastro.2009.06.059. [DOI] [PubMed] [Google Scholar]
  • 131.Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ, et al. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis. 2005;192:258–65. doi: 10.1086/430949. [DOI] [PubMed] [Google Scholar]
  • 132.Kondo Y, Sung VM, Machida K, Liu M, Lai MM. Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. Virology. 2007;361:161–73. doi: 10.1016/j.virol.2006.11.009. [DOI] [PubMed] [Google Scholar]
  • 133.Ludwig IS, Lekkerkerker AN, Depla E, Bosman F, Musters RJ, Depraetere S, et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol. 2004;78:8322–32. doi: 10.1128/JVI.78.15.8322-8332.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Dominguez-Villar M, Fernandez-Ponce C, Munoz-Suano A, Gomez E, Rodríguez-Iglesias M, Garcia-Cozar F. Up-regulation of FOXP3 and induction of suppressive function in CD4+ Jurkat T-cells expressing hepatitis C virus core protein. Clin Sci (Lond) 2012;123:15–27. doi: 10.1042/CS20110631. [DOI] [PubMed] [Google Scholar]
  • 135.Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711. doi: 10.1146/annurev.immunol.21.120601.141040. [DOI] [PubMed] [Google Scholar]
  • 136.Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111–65. doi: 10.1016/B978-0-12-380995-7.00004-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun. 2010;34:1–6. doi: 10.1016/j.jaut.2009.08.008. [DOI] [PubMed] [Google Scholar]
  • 138.Bamboat ZM, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP, et al. Human liver dendritic cells promote T cell hyporesponsiveness. J Immunol. 2009;182:1901–11. doi: 10.4049/jimmunol.0803404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139.Cobbold SP, Adams E, Nolan KF, Regateiro FS, Waldmann H. Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link. Immunol Rev. 2010;236:203–18. doi: 10.1111/j.1600-065X.2010.00913.x. [DOI] [PubMed] [Google Scholar]

Articles from Virulence are provided here courtesy of Taylor & Francis

RESOURCES